Linked Life Data

21270282

Source:http://linkedlifedata.com/resource/pubmed/id/21270282

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2011-4-8
pubmed:abstractText
We previously showed that recombinant (r) Listeria monocytogenes carrying ?actA and a selected prfA* mutation (r-Listeria ?actA prfA*) secreted >100-fold more immunogen in broth culture than wild-type r-Listeria or r-Listeria ?actA and elicited much greater cellular and humoral immune responses than r-Listeria ?actA after intravenous vaccination of mice. Here, we conducted comparative studies evaluating vaccine-elicited immune responses in systemic and mucosal sites after intranasal, intravenous, intraperitoneal, or subcutaneous immunization of mice with r-Listeria ?actA prfA* vaccine candidates. Intranasal vaccination of mice with r-Listeria ?actA prfA* vaccine candidates elicited a robust gamma interferon-positive (IFN-?(+)) cellular response in systemic sites, although intravenous or intraperitoneal immunization was more efficient. Surprisingly, intranasal vaccination elicited an appreciable pulmonary IFN-?(+) cellular response that was nonstatistically higher than the magnitude induced by the intravenous route but was significantly greater than that elicited by subcutaneous immunization. Furthermore, although intranasal r-Listeria ?actA prfA* delivery induced poor systemic IgG responses, intranasal vaccination elicited appreciable secretory immunogen-specific IgA titers that were similar to or higher in mucosal fluid than those induced by subcutaneous and intravenous immunizations. Thus, intranasal vaccination with r-Listeria ?actA prfA* appears to be a useful approach for eliciting robust systemic and pulmonary cellular responses and measurable secretory mucosal IgA titers.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1556-679X
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
18
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
640-6
pubmed:dateRevised
2011-10-3
pubmed:meshHeading
pubmed-meshheading:21270282-Administration, Intranasal, pubmed-meshheading:21270282-Animals, pubmed-meshheading:21270282-Antibodies, Bacterial, pubmed-meshheading:21270282-Bacterial Proteins, pubmed-meshheading:21270282-Bacterial Vaccines, pubmed-meshheading:21270282-Female, pubmed-meshheading:21270282-Immunoglobulin A, Secretory, pubmed-meshheading:21270282-Injections, Intraperitoneal, pubmed-meshheading:21270282-Injections, Intravenous, pubmed-meshheading:21270282-Injections, Subcutaneous, pubmed-meshheading:21270282-Listeria monocytogenes, pubmed-meshheading:21270282-Lung, pubmed-meshheading:21270282-Membrane Proteins, pubmed-meshheading:21270282-Mice, pubmed-meshheading:21270282-Mice, Inbred BALB C, pubmed-meshheading:21270282-Peptide Termination Factors, pubmed-meshheading:21270282-Vaccination, pubmed-meshheading:21270282-Vaccines, Attenuated
pubmed:year
2011
pubmed:articleTitle
Intranasal vaccination with the recombinant Listeria monocytogenes ?actA prfA* mutant elicits robust systemic and pulmonary cellular responses and secretory mucosal IgA.
pubmed:affiliation
Department of Microbiology and Immunology, University of Illinois College of Medicine, Chicago, Illinois 60612, USA.
pubmed:publicationType
Journal Article, Research Support, N.I.H., Extramural